Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis
about
Role of tyrosine-kinase inhibitors in myeloproliferative neoplasms: comparative lessons learnedOvercoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinibRationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosisBlast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factorsThe Role of Reactive Oxygen Species in Myelofibrosis and Related NeoplasmsPolycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617FPolycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and managementCIViC databaseRuxolitinib: A Review in Polycythaemia Vera.Managing patients with myelofibrosis and low platelet counts.Disease characteristics and outcomes in younger adults with primary and secondary myelofibrosis.Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial.Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis.The Amelioration of Myelofibrosis with Thrombocytopenia by a JAK1/2 Inhibitor, Ruxolitinib, in a Post-polycythemia Vera Myelofibrosis Patient with a JAK2 Exon 12 MutationComparison of the Mutational Profiles of Primary Myelofibrosis, Polycythemia Vera, and Essential ThrombocytosisMulticenter Retrospective Analysis of Turkish Patients with Chronic Myeloproliferative Neoplasms.Targeting phosphatidylinositol-3-kinase pathway for the treatment of Philadelphia-negative myeloproliferative neoplasms.Myeloproliferative neoplasms (MPNs) have a significant impact on patients' overall health and productivity: the MPN Landmark survey.New Strategies in Myeloproliferative Neoplasms: The Evolving Genetic and Therapeutic Landscape.Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteriaMutant calreticulin-expressing cells induce monocyte hyperreactivity through a paracrine mechanismNovel and emerging therapies for the treatment of polycythemia veraRisk of second primary malignancies in a population-based study of adult patients with essential thrombocythemiaClinical Manifestation of Calreticulin Gene Mutations in Essential Thrombocythemia without Janus Kinase 2 and MPL Mutations: A Chinese Cohort Clinical Study.From leeches to personalized medicine: evolving concepts in the management of polycythemia vera.Coexistence of JAK2 and CALR mutations and their clinical implications in patients with essential thrombocythemia.Splanchnic vein thrombosis in myeloproliferative neoplasms: pathophysiology and molecular mechanisms of disease.Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms.Definition and management of ruxolitinib treatment failure in myelofibrosis.Molecular genetic evaluation of myeloproliferative neoplasms.Management of side effects of BCR/ABL-negative chronic myeloproliferative neoplasm therapies. Focus on anagrelide.Oncogenic Drivers in Myeloproliferative Neoplasms: From JAK2 to Calreticulin Mutations.How we diagnose and treat essential thrombocythaemia.Myeloproliferative neoplasms: A decade of discoveries and treatment advances.Gender and survival in essential thrombocythemia: A two-center study of 1,494 patients.Leukemic transformation in patients with myeloproliferative neoplasms: a population-based retrospective study.The evolution and clinical relevance of prognostic classification systems in myelofibrosis.Myeloproliferative neoplasms: Morphology and clinical practice.European LeukemiaNet study on the reproducibility of bone marrow features in masked polycythemia vera and differentiation from essential thrombocythemia.Age-Related Macular Degeneration in Patients With Chronic Myeloproliferative Neoplasms.
P2860
Q26738514-0F9B671E-8063-40BC-9A2A-6652E95BDD6BQ26750696-BA412B5D-03D0-4BD3-9518-2131D67B6B72Q26772881-FC93B748-F6BE-43D6-A8E5-BDEF134BA671Q26777265-A4DCE010-E93F-4DCA-A4C7-624A02C0C476Q26779929-C7AA2033-7A9C-4B4E-8B39-7E4439FC2835Q26795666-71296227-5284-4131-82C1-0023C8A752F3Q26851894-6F9ACCE6-756B-4C34-B438-66EE41705F83Q27612411-C55E988D-3ED0-4C6B-85CE-FEAB7DEEA48AQ33425781-8448F5F2-5346-4CFA-B4DA-A7A91753E5E7Q33432406-55A08806-6F64-4868-8375-A93EEE36D13BQ33433006-208C6C50-9599-42E7-95F7-520DF1FCF450Q33439559-4DC709E4-51AD-470A-819E-687A5B678BA7Q33442613-E6361BA7-7B06-44CF-9248-1B1F25636886Q33443246-521E7CE7-2FD2-4A3A-A5F4-8215F1506C2FQ33595912-538261B6-3F11-4EEC-84D1-1C59AB784DF8Q33747797-8951D496-F122-4C0D-AA47-8FEAD4B93C0AQ35727453-1C47184C-42D3-439F-B981-96FCA26B1ADFQ35938283-C14186CD-94EC-4183-BF0D-2E14CEAC4533Q36782943-9D535A8B-51A3-49AF-816B-9D63ACA8061FQ36874807-AAADA904-0832-4910-B37E-0F2DCCB8138BQ36927348-15C6F567-2BD0-4A74-8F34-5A3B281B3BFCQ37069633-A0D938D7-8DBA-4FCF-8BE2-0866B2F8DA75Q37153294-96CD3BFC-95C0-4821-B7AF-FA42B4893CB4Q37157892-BDDB8745-B679-4ECA-8F78-BE471E8BD633Q37555790-3267D52A-E697-4F11-A430-19CB440F81D5Q37636747-5B8EE2B9-3222-44DD-8512-63368006607BQ37638779-CC0DB80A-D6A0-4CC9-8815-B027A53629DEQ37679175-2AB8884A-E91A-4F87-B7AB-8E7B986C69F0Q38287012-A98CBEAC-E01F-48B6-BFDF-35DA53B86C60Q38481945-CDABE70A-74D1-4EBA-AAFD-98995A20104BQ38586505-CBE7B698-0D2C-4977-991C-96A816407A38Q38586919-689604DD-97CC-4D1B-AC48-FF16D717356AQ38606595-2B704DE0-5BB1-4010-ACFE-9D26F191FBE1Q38613880-ED2CEFED-E1A3-4CEF-910E-7D27DFF075DFQ38631064-A76A4D46-CEFD-4319-A94A-03D9A54B81C8Q38673830-45FADB2A-04C8-490B-B697-7180EB840316Q38683077-CD6ABEDE-6477-483A-A98D-C66922FB8AFFQ38683559-73DCA3E2-C3E8-40DC-8A1C-70AB43D5086CQ38689790-37EC9E0B-F10E-46D0-B173-2B40FCF83D33Q38706624-BE3F8071-8688-460F-A5B6-7A28B22A9D2F
P2860
Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis
description
2014 nî lūn-bûn
@nan
2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
name
Long-term survival and blast t ...... themia vera, and myelofibrosis
@ast
Long-term survival and blast t ...... themia vera, and myelofibrosis
@en
Long-term survival and blast t ...... hemia vera, and myelofibrosis.
@nl
type
label
Long-term survival and blast t ...... themia vera, and myelofibrosis
@ast
Long-term survival and blast t ...... themia vera, and myelofibrosis
@en
Long-term survival and blast t ...... hemia vera, and myelofibrosis.
@nl
altLabel
Long-term survival and blast t ...... themia vera, and myelofibrosis
@en
prefLabel
Long-term survival and blast t ...... themia vera, and myelofibrosis
@ast
Long-term survival and blast t ...... themia vera, and myelofibrosis
@en
Long-term survival and blast t ...... hemia vera, and myelofibrosis.
@nl
P2093
P2860
P50
P3181
P1433
P1476
Long-term survival and blast t ...... themia vera, and myelofibrosis
@en
P2093
Alem A Belachew
Alessandro M Vannucchi
Alessandro Rambaldi
Animesh Pardanani
Ayalew Tefferi
Christy Finke
Curtis A Hanson
Dirk R Larson
Emnet A Wassie
Guido Finazzi
P2860
P304
2507-13; quiz 2615
P3181
P356
10.1182/BLOOD-2014-05-579136
P407
P577
2014-10-16T00:00:00Z